Form 4: Neumora COO Sells Shares Under 10b5-1 Plan

Neumora Therapeutics' Chief Operating and Development Officer, Daljit Singh Aurora, sold 114,703 shares of common stock for $2.6767 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Daljit Singh Aurora, Chief Operating and Development Officer of Neumora Therapeutics, Inc. (NMRA), reported a sale of common stock.
• The transaction involved the disposition of 114,703 shares of Neumora Therapeutics common stock.
• The shares were sold at a weighted average price of $2.6767 per share, with individual trades ranging from $2.65 to $2.81.
• The sale occurred on November 11, 2025, and was executed pursuant to a Rule 10b5-1 trading plan adopted on April 22, 2024.
• Following the transaction, Daljit Singh Aurora directly holds 0 shares of common stock.
• Daljit Singh Aurora indirectly holds 88,935 shares through the Aurora Family Trust.

Sentiment

Score: 5

Explanation: The filing reports an insider sale of common stock, which can be perceived negatively. However, the sale was conducted under a pre-arranged 10b5-1 trading plan, which mitigates the negative sentiment by indicating a scheduled transaction rather than a reaction to new, undisclosed information.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, adopted on April 22, 2024, indicating a pre-scheduled transaction rather than an immediate reaction to new, undisclosed information.

Negatives

• Daljit Singh Aurora, a key officer, sold a significant number of shares (114,703 shares) of company common stock.
• The direct beneficial ownership of the reporting person is now 0 shares following this transaction.

Future Outlook

NA

Management Comments

• The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 22, 2024.

Industry Context

This filing is specific to an insider transaction at Neumora Therapeutics and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may view the insider sale as a slight negative, though the pre-arranged 10b5-1 plan mitigates concerns about the timing of the sale.

Key Dates

Recommendation

The filing reports a significant insider sale by a key officer. While the sale was executed under a pre-arranged 10b5-1 plan, which suggests it's not based on new, adverse information, a large insider sale can still create downward pressure or negative sentiment. Given the lack of other operational or financial updates in this Form 4, a 'hold' recommendation is appropriate as investors should await further company-specific news or broader market trends before making a definitive buy or sell decision.

Keywords

Neumora Therapeutics, NMRA, Insider Trading, Form 4, Stock Sale, Daljit Singh Aurora, 10b5-1 Plan, Officer Transaction